Literature DB >> 22613402

Current treatment of sacral giant cell tumour of bone: a review.

C C Shen1, H Li, Z L Shi, H M Tao, Z M Yang.   

Abstract

Sacral giant cell tumour of bone has an insidious onset and slow growth rate, making early diagnosis difficult. The tumour has a high recurrence rate and is often fatal. Magnetic resonance imaging and computed tomography (CT), including CT-guided fine-needle biopsy, are useful for early diagnosis. Although therapy for sacral giant cell tumour often involves surgical resection and reconstruction challenges, improvements in various treatment modalities, including arterial embolization and radiotherapy, have widened the effective treatment options. The current surgical and adjuvant treatment modalities available for the management of sacral giant cell tumour are systematically reviewed and a suggested treatment algorithm is provided. En bloc excision remains the surgical procedure of choice, with functional reconstruction important in cases where the lesion is high in the sacrum. The use of adjuvant radiotherapy and chemotherapy remains controversial and should be studied further. Determination of the optimum treatment for sacral giant cell tumour will require randomized controlled trials. Early diagnosis, complete surgical resection with tumour-free margins and comprehensive treatment are important for local tumour control and improved outcome.

Entities:  

Mesh:

Year:  2012        PMID: 22613402     DOI: 10.1177/147323001204000203

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  10 in total

1.  Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.

Authors:  Noah Federman; Earl W Brien; Vivek Narasimhan; Sarah M Dry; Monish Sodhi; Sant P Chawla
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

Review 2.  Axial giant cell tumor - current standard of practice.

Authors:  Navaneeth Kamath; Jasmine Agarwal; Ashish Gulia
Journal:  J Clin Orthop Trauma       Date:  2019-10-09

3.  In situ cryoablation of sacral Giant Cell Tumor using three-dimensional (3D) model: A case report.

Authors:  Avital Elias; Amit Benady; Eran Golden; Ortal Segal; Solomon Dadia
Journal:  J Orthop       Date:  2022-02-10

4.  Biological characteristics of a novel giant cell tumor cell line derived from spine.

Authors:  Zhenhua Zhou; Yan Li; Leqin Xu; Xudong Wang; Su Chen; Cheng Yang; Jianru Xiao
Journal:  Tumour Biol       Date:  2016-01-23

5.  Synchronous Multicentric Giant Cell Tumour of Distal Radius and Sacrum with Pulmonary Metastases.

Authors:  Varun Sharma Tandra; Krishna Mohan Reddy Kotha; Moorthy Gadisetti Venkata Satyanarayana; Kali Varaprasad Vadlamani; Vyjayanthi Yerravalli
Journal:  Case Rep Oncol Med       Date:  2015-05-27

6.  Modified kraske procedure with mid-sacrectomy and coccygectomy for en bloc excision of sacral giant cell tumors.

Authors:  Vítor M Gonçalves; Alvaro Lima; João Gíria; Nuno Carvalho; José Parreira; Manuel Cunha E Sá
Journal:  Case Rep Surg       Date:  2014-10-16

Review 7.  Giant cell tumor of axial vertebra: surgical experience of five cases and a review of the literature.

Authors:  Guojing Chen; Jing Li; Xiangdong Li; Hongbin Fan; Zheng Guo; Zhen Wang
Journal:  World J Surg Oncol       Date:  2015-02-18       Impact factor: 2.754

8.  Should Denosumab or Radical Surgery Be Recommended for a Spinal Giant Cell Tumour in a Fertile Female?

Authors:  Harshadkumar Dhirajlal Rajgor; Steven James; Rajesh Botchu; Melvin Grainger; Marcin Czyz
Journal:  Cureus       Date:  2020-11-17

9.  Surgical Outcomes in Patients with High Spinal Instability Neoplasm Score Secondary to Spinal Giant Cell Tumors.

Authors:  Benjamin D Elder; Eric W Sankey; C Rory Goodwin; Thomas A Kosztowski; Sheng-Fu L Lo; Ali Bydon; Jean-Paul Wolinsky; Ziya L Gokaslan; Timothy F Witham; Daniel M Sciubba
Journal:  Global Spine J       Date:  2015-06-15

Review 10.  State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics.

Authors:  Anna Parmeggiani; Marco Miceli; Costantino Errani; Giancarlo Facchini
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.